Accustem Logo

The commercialisation of StemPrintER and its next generation derivative SPARE, the multi-gene prognostic assay intended for the prediction of risk of recurrence in luminal, ER+/HER2- breast cancer patients.

Multigene prognostic tests can assist decision making on treatments, differentiating low risk patients who could be spared chemotherapy from higher risk patients who might benefit from chemotherapy or prolonged endocrine treatments.

Find out more

Technology

StemPrintER was developed to be a novel genomic predictor based on 20 stem cell genes. These 20 genes have high expression levels that identify a similar group of patients with negative results from four distinct public breast cancer datasets.

Find out more

Our Team

Directors

Gabriele Cerrone

Gabriele Cerrone

Dr Kunwar Shailubhai

Dr Kunwar Shailubhai

Will Simon

Willy Simon

John Brancaccio

John Brancaccio

Contact

UK Headquarters

Accustem
55 Park Lane
London W1K 1NA
United Kingdom